Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Pfizer, inc. save search
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
Published: 2022-06-16 (Crawled : 11:00) - ir.akerotx.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
HTGC F | $18.25 0.5% -0.27% 550K
|
Finance
|
| O: -2.88%
H: 1.33%
C: 0.08%
AKRO | $20.51 -5.05% -5.19% 560K
|
Health Technology
|
| O: 17.77%
H: 14.88%
C: 10.2%
therapeutics
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
Published: 2022-01-31 (Crawled : 12:30) - prnewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.61%
H: 0.26%
C: -2.43%
IONS | $40.81 -0.24% -0.25% 990K
|
Health Technology
|
| O: -10.54%
H: 12.88%
C: 12.21%
program
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
Published: 2023-02-03 (Crawled : 15:00) - globenewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.03%
H: 0.08%
C: -0.67%
CLLS | $2.47 0.41% 0.4% 15K
|
Health Technology
|
| O: -30.67%
H: 12.39%
C: 11.06%
offering announcement
Arvinas Announces Oversubscribed $350 Million Private Placement
Published: 2023-11-27 (Crawled : 12:00) - globenewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: -1.98%
ARVN | $34.29 2.51% 2.48% 800K
|
Health Technology
|
| O: 2.51%
H: 11.93%
C: 7.54%
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
Published: 2022-03-15 (Crawled : 23:00) - globenewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
BNTX | $86.17 -0.27% -0.24% 520K
|
Health Technology
|
| O: 1.63%
H: 11.55%
C: 11.21%
covid-19 covid authorization vaccine tiona merge order emergency use authorization
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24 (Crawled : 17:00) - prnewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.39%
H: 0.82%
C: -0.74%
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
|
| O: 0.22%
H: 0.43%
C: -0.39%
SRNE | $0.024 -14.29% -8.85% 57K
|
Health Technology
|
| O: -63.33%
H: 263.64%
C: 127.27%
GILD | News | $66.16 -1.15% -1.16% 4.9M
|
Health Technology
|
| O: 0.1%
H: 0.43%
C: -0.04%
AUTL | $4.8 -0.83% -0.83% 1.2M
|
Health Technology
|
| O: -0.91%
H: 11.52%
C: 4.94%
drug report t-cell global therapy market
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.9%
H: 2.03%
C: 1.89%
VERU | $1.42 22.41% 18.31% 6.9M
|
Health Technology
|
| O: -0.53%
H: 2.22%
C: -3.59%
ALT | $6.89 -2.13% -2.03% 2.7M
|
Commercial Services
|
| O: 0.3%
H: 11.41%
C: 9.8%
medical program
Global Vulvovaginal Candidiasis Treatment Market Research Report 2023-2028 - Demand for Cost-effective Vulvovaginal Candidiasis Treatment Soars with Growing Geriatric Population
Published: 2023-10-04 (Crawled : 23:00) - prnewswire.com
ALPMY | $9.47 0.11% -1.11% 520K
|
Manufacturing
|
| O: 0.59%
H: 0.29%
C: 0.22%
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.42%
H: 0.99%
C: 0.06%
SCYX | $1.405 -1.06% 3.4% 80K
|
Health Technology
|
| O: 0.45%
H: 4.04%
C: 0.45%
CDTX | $0.722 -0.03% -0.29% 270K
|
Health Technology
|
| O: 0.39%
H: 10.33%
C: 3.9%
report treatment candidiasis research global growing market
Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer
Published: 2022-10-31 (Crawled : 15:00) - biospace.com/
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.74%
H: 0.65%
C: -1.13%
GOSS 4 | $0.806 -1.71% -2.5% 770K
|
Health Technology
|
| O: -0.38%
H: 6.05%
C: 5.71%
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 0.79%
H: 10.24%
C: 8.66%
therapeutics financial
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
Published: 2021-09-20 (Crawled : 17:00) - prnewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -1.74%
H: 2.9%
C: 1.87%
MRK | $125.23 -0.11% -0.54% 3.4M
|
Health Technology
|
| O: -0.14%
H: 2.04%
C: 1.08%
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.18%
H: 1.22%
C: -0.23%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.52%
H: 9.63%
C: 3.06%
space cancer spac therapy
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Published: 2021-01-26 (Crawled : 12:00) - globenewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.03%
H: 0.89%
C: 0.11%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 4.44%
H: 9.52%
C: 4.67%
positive therapy phase 3
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
Published: 2022-04-12 (Crawled : 05:00) - globenewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -1.17%
H: 1.18%
C: -0.36%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -22.06%
H: 9.34%
C: -3.89%
myfembree management drug application
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
Published: 2021-05-26 (Crawled : 21:00) - biospace.com/
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.1%
H: 0.03%
C: -0.94%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 0.26%
H: 8.97%
C: 3.63%
treatment fda bleeding fda approval approval menstrual bleeding
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Published: 2021-11-22 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -1.72%
H: 1.02%
C: 0.49%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
BNTX | $86.17 -0.27% -0.24% 520K
|
Health Technology
|
| O: 7.04%
H: 8.12%
C: 7.96%
covid vaccine phase 3 trial
Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update
Published: 2021-05-13 (Crawled : 01:00) - achievelifesciences.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.35%
H: 0.2%
C: -0.55%
ACHV | $4.57 -0.11% 78K
|
Health Technology
|
| O: 3.22%
H: 8.07%
C: 1.29%
financial results results
Biotechs Step Up Development Activities as U.S. Government Prioritizes Availability Of COVID-19 Vaccines
Published: 2021-03-15 (Crawled : 13:00) - prnewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.2%
H: 1.2%
C: 1.14%
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: 0.09%
H: 0.57%
C: 0.42%
NVAX | $3.89 0.26% 2.1M
|
Health Technology
|
| O: 0.27%
H: 7.58%
C: 6.95%
MRNA S | $102.0 -1.39% -1.4% 1.4M
|
Health Technology
|
| O: -0.16%
H: 5.18%
C: 5.04%
BNTX | $86.17 -0.27% -0.24% 520K
|
Health Technology
|
| O: 0.69%
H: 4.0%
C: 3.74%
covid biotech vaccine iot covid-19
ZyVersa Therapeutics Appoints Three New Board Members
Published: 2023-01-05 (Crawled : 15:00) - prnewswire.com
FWBI | $2.84 -2.07% -2.84% 30K
|
Manufacturing
|
| O: 1.82%
H: 14.29%
C: 2.68%
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.8%
H: 0.52%
C: -0.14%
AXGN | $6.55 -5.62% -5.95% 240K
|
Health Technology
|
| O: -1.33%
H: 7.56%
C: 6.95%
therapeutics
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
Published: 2023-05-03 (Crawled : 12:20) - biospace.com/
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.36%
H: 0.48%
C: -1.91%
DCPH | $14.23 -3.33% -3.41% 760K
|
Health Technology
|
| O: -6.99%
H: 7.22%
C: 4.74%
pharmaceuticals financial results
US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Published: 2021-01-04 (Crawled : 14:00) - biospace.com/
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.16%
H: 0.19%
C: -0.16%
OPK | $1.23 -1.6% -1.21% 3.4M
|
Health Technology
|
| O: 2.03%
H: 7.19%
C: 4.22%
growth fda submission growth hormone hormone fda acceptance
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: -1.77%
TNXP | $0.157 -1.51% -2.91% 1.4M
|
Health Technology
|
| O: 4.32%
H: 7.17%
C: 2.5%
drug fibromyalgia study
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.